Physician profile
Nicholas Hoffman
NPI 1245089549
$1,179.02
in general payments reported to CMS, 2019-2025
23 companies · $777 in 2025
The $777 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $402 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $247.18 | 2024-2025 | Lonsurf, Inqovi |
| Genzyme Corporation | $123.22 | 2025 | |
| Abbvie INC. | $97.66 | 2024-2025 | |
| Daiichi Sankyo INC. | $85.40 | 2025 | Datroway, Enhertu |
| Astrazeneca Pharmaceuticals LP | $69.81 | 2024-2025 | Tagrisso, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $64.88 | 2025 | |
| Novartis Pharmaceuticals Corporation | $58.24 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $54.33 | 2024-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $49.97 | 2024-2025 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $38.90 | 2024-2025 | Fruzaqla |
| Galvanize Therapeutics, INC | $35.65 | 2025 | Aliya System |
| Pharmacosmos Therapeutics INC. | $34.89 | 2024-2025 | Monoferric, Cosela |
| Eisai INC. | $33.13 | 2025 | |
| Emd Serono, INC. | $28.11 | 2024 | |
| Blueprint Medicines Corporation | $19.86 | 2024 | Ayvakit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $19.24 | 2025 | Optune Lua (Novottf-200t) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.69 | 2025 | |
| Janssen Scientific Affairs, LLC | $18.61 | 2024 | Rybrevant |
| Incyte Corporation | $18.48 | 2025 | Zynyz, Monjuvi |
| Janssen Biotech, INC. | $16.92 | 2025 | Rybrevant |
| Acrotech Biopharma INC. | $16.70 | 2025 | Ryzneuta |
| Aimmune Therapeutics, INC. | $14.99 | 2025 | Zenpep |
| Cumberland Pharmaceuticals, INC. | $14.16 | 2024 | Sancuso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.